SCHOTT Doubles Production Capacity for Polymer Syringes
New line in Swiss facility produces ready-to-fill syringes.
SCHOTT installed a new line in its St. Gallen, Switzerland facility to manufacture small-size (1 to 10 mL), ready-to-fill syringes made of cyclic olefin copolymer (COC), the company noted in a press release. This expansion doubles SCHOTT’s production capacity for COC syringes.
COC is an inert material that is compatible with a broad range of drugs. SCHOTT says its syringes have excellent barrier properties and glass-like transparency and are break-resistant and lightweight. The syringes are manufactured in cleanrooms using a fully automated process from injection molding to the final packaging. The syringes are sterilized and are ready for aseptic-filling operations.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
